Tuberous Sclerosis

• mTOR pathway dysregulation and uncontrolled cellular growth: The TSC1-TSC2 complex normally functions as a GTPase-activating protein (GAP) that converts active Rheb-GTP to inactive Rheb-GDP, thereby suppressing mechanistic target of rapamycin complex 1 (mTORC1). When either TSC1 or TSC2 is mutated or absent, Rheb accumulates in its active GTP-bound state, leading to constitutive mTORC1 activation. This results in unopposed phosphorylation of downstream effectors including S6 kinase and 4E-BP1, promoting protein synthesis, lipid synthesis, and metabolic reprogramming. The consequence is loss of the normal "growth brake" that TSC provides, leading to unchecked cellular proliferation, increased cell size (hence the term "tuberous" lesions), and formation of hamartomas—benign but problematic tumors composed of cells normally found in that tissue but in an abnormal, disorganized arrangement.

• Two-hit mechanism and tumor development: Although TSC is inherited in an autosomal dominant pattern (requiring only one mutant allele for disease manifestation), the development of actual hamartomas and tumors typically requires a second somatic mutation (Knudson's "two-hit" hypothesis) affecting the remaining wild-type allele in specific cell lineages. This explains the multifocal nature of TSC lesions—different cell clones acquire independent second hits, resulting in multiple separate tumors. The cells carrying two mutant alleles experience profound mTORC1 activation and proliferate at a selective advantage compared to surrounding normal tissue, resulting in macroscopic hamartomas.

• Neurological manifestations through dysregulated neurogenesis and dendritic spine development: In the developing brain, TSC mutations lead to cortical tubers—areas of abnormal neuronal migration and architecture resulting from uncontrolled mTORC1 activity affecting neural progenitor cell proliferation, migration, and differentiation. mTORC1 hyperactivation promotes excessive dendritic spine formation and abnormal synaptic connectivity, creating a hyperexcitable neuronal network prone to seizures. Additionally, TSC-related disruption of normal neurogenesis contributes to cognitive disability. The cortical tubers themselves appear as areas of cortical thickening with abnormal lamination on histology, creating focal areas of neural dysfunction and epileptogenicity. The location and number of cortical tubers correlate with seizure severity and cognitive outcomes.

• Renal involvement through altered tubular cell proliferation and cyst formation: In the kidney, TSC mutations drive the development of angiomyolipomas (benign tumors composed of blood vessels, smooth muscle, and fat) and renal cysts through uncontrolled smooth muscle cell proliferation. The hyperactivated mTORC1 pathway promotes excessive cell survival signals and resistance to apoptosis, allowing these cells to accumulate. Angiomyolipomas carry risk for spontaneous hemorrhage and can progress to renal failure. Renal cysts develop through a related mechanism of tubular epithelial cell proliferation and dedifferentiation.

• Cutaneous manifestations through altered melanocyte and fibroblast function: Facial angiofibromas (historically called "adenoma sebaceum," though they are not sebaceous gland tumors) and other skin lesions result from mTORC1-driven proliferation of dermal fibroblasts and vascular endothelial cells. TSC mutations in melanocytes and surrounding cells promote abnormal growth of the skin hamartomas characteristic of this condition. Hypomelanotic macules appear early in life due to reduced melanin production in focal skin areas, likely from altered development of melanocyte-containing regions.

• Cardiac involvement through myocyte proliferation: Cardiac rhabdomyomas develop through TSC-related hyperactivation of mTORC1 in cardiac myocytes, leading to benign hamartomatous growth. These tumors often regress spontaneously as mTORC1 activity is partially normalized with age and maturation, though large tumors can cause obstruction or arrhythmias.

• TSC1 gene mutations (chromosome 9q34): Account for approximately 50-85% of inherited TSC cases. TSC1 mutations are associated with a relatively milder phenotype and lower seizure risk compared to TSC2 mutations. Affected individuals inherit a mutant TSC1 allele from a heterozygous parent with variable penetrance and expressivity, or acquire de novo mutations. TSC1-only mutations generally confer better neurological prognosis but still require organ surveillance.

• TSC2 gene mutations (chromosome 16p13.3): Account for approximately 15-50% of inherited cases and are associated with earlier and more severe disease manifestation, including higher rates of infantile spasms (West syndrome), intellectual disability, and more numerous cortical tubers. TSC2 mutations result in a more aggressive phenotype, likely because TSC2 has additional TSC1-independent functions and TSC2 protein is less stable when TSC1 is absent. Deletions involving the TSC2 locus (particularly large deletions) are associated with worse outcomes and may include contiguous gene syndrome when adjacent genes are affected.

• De novo mutations: Approximately one-third of TSC cases result from new (de novo) mutations arising in the germline of an unaffected parent. These patients have a 50% recurrence risk in offspring but their parents have no elevated recurrence risk. De novo mutations occur at approximately equal rates in TSC1 and TSC2. The presence of de novo mutations makes family screening and genetic counseling essential even in apparently sporadic cases.

• Genetic anticipation and modifier genes: While TSC generally does not show strong anticipation (worsening with successive generations), some variation in severity among family members suggests the role of modifier genes and environmental factors. Epigenetic modifications and potential polygenic factors may influence phenotypic severity, though these are not well-characterized.

• No secondary causes: Unlike some genetic conditions, TSC is exclusively caused by germline mutations in TSC1 or TSC2; there are no acquired or secondary forms of tuberous sclerosis. However, somatic TSC mutations in specific tissues (lymphangioleiomyomatosis in the lung, for example) may occur independently.

• Seizures and infantile spasms (most common neurological manifestation): Occur in 75-90% of TSC patients, making them the most frequent neurological presentation. Seizures typically begin in infancy or early childhood, with a median onset around 4-6 months of age. Infantile spasms (West syndrome), characterized by brief flexion or extension spasms in clusters, occur in 10-40% of TSC cases and constitute a medical emergency requiring prompt treatment. Generalized tonic-clonic, focal, atypical absence, and myoclonic seizures are all common. The seizures often are refractory to antiepileptic drugs (30-40% of TSC patients have drug-resistant epilepsy). The physiological basis involves abnormal neuronal excitability in cortical tubers due to disrupted cytoarchitecture, altered neurotransmitter signaling, and abnormal inhibitory circuits. Seizure severity correlates with the number and location of cortical tubers.

• Cognitive disability and developmental delay: Present to varying degrees in 40-60% of TSC patients. Ranges from mild learning difficulties to severe intellectual disability. Onset typically becomes apparent in early childhood when developmental milestones are evaluated. The degree of cognitive impairment correlates with seizure severity, cortical tuber burden, and white matter abnormalities. Early-onset seizures, particularly infantile spasms, are strong predictors of cognitive disability. Pathophysiology involves both direct effects of cortical tubers on brain function and secondary effects of recurrent seizures on developing neural networks.

• Facial angiofibromas (formerly "adenoma sebaceum"): Present in 75-80% of TSC patients, typically appearing between ages 3-10 years, though may appear as early as infancy or as late as adolescence. Appear as small (1-5 mm), flesh-colored to pink or red papules and nodules distributed symmetrically on the cheeks, nose, chin, and forehead. These are not sebaceous gland tumors despite the historical misnomer but rather benign hamartomas composed of fibroblasts and vascular tissue. Often mistaken for acne vulgaris in adolescents. Cosmetically significant but benign, though may be managed with laser therapy or topical retinoids for cosmetic improvement.

• Hypomelanotic macules (ash-leaf spots): Present in 90% of TSC patients, often the earliest clinical sign, and can appear in infants and young children before seizures develop. Hypopigmented (not completely depigmented) ovoid or "ash-leaf" shaped macules, typically 0.5-3 cm in size, found on the trunk, extremities, and occasionally the face. Best visualized under Wood's lamp examination in reduced lighting, which enhances the contrast. These lesions are completely benign and do not evolve into other skin manifestations. The presence of three or more hypomelanotic macules is a major diagnostic criterion. Represent areas of reduced melanin production and are thought to result from abnormal migration or function of melanoblasts during embryogenesis in TSC-affected skin.

• Confetti skin lesions: Appear in 10-20% of patients, consisting of multiple small (1-3 mm), round hypopigmented macules giving a "confetti" or "sprinkled" appearance, distinct from the larger ash-leaf macules. Represent a more diffuse pattern of melanocyte dysfunction.

• Periungual and subungual fibromas: Present in 15-40% of TSC patients, typically appearing in adolescence or adulthood. Small flesh-colored or pink nodules arising from the nail bed or periungual tissue, often multiple and bilateral. Benign but may interfere with nail growth or cause discomfort. More common in TSC2 mutation carriers.

• Shagreen patches: Occur in 20-40% of patients, representing localized areas of connective tissue overgrowth, typically appearing as slightly elevated, dimpled or orange-peel-textured skin patches usually on the lower back or sacral region. Composed of excess collagen and elastic fibers in the dermis. Benign but cosmetically notable.

• Cardiac rhabdomyomas: Present in 30-50% of TSC patients on cardiac imaging, though many are asymptomatic. Most commonly detected prenatally or in infancy via echocardiography. These benign cardiac hamartomas are composed of disorganized cardiac muscle cells. Large tumors can obstruct blood flow (particularly if located in the ventricular outflow tract or across valves), cause dysrhythmias, or interfere with cardiac conduction. The natural history typically involves regression or stabilization with age. Small asymptomatic rhabdomyomas require only surveillance; those causing hemodynamic compromise or dysrhythmias may require intervention. Their presence in a neonate or infant is highly suggestive of TSC.

• Renal angiomyolipomas (AMLs): Develop in 80-90% of TSC patients, though many remain small and asymptomatic. Present typically in adolescence or adulthood but can be detected on prenatal ultrasound. Benign hamartomas composed of blood vessels (angioma), smooth muscle, and fat. The major clinical concern is spontaneous hemorrhage, which can occur with large tumors (especially >4 cm) and presents with flank pain, hematuria, and hemodynamic instability. Chronic complications include progressive renal insufficiency, especially with bilateral multifocal involvement. Imaging typically shows characteristic fat density on CT or MRI (the fat content distinguishes them from renal cell carcinoma). Small asymptomatic AMLs are monitored; large or hemorrhaging tumors may require embolization, nephron-sparing partial nephrectomy, or mTOR inhibitor therapy.

• Renal cysts: Develop in 20-30% of TSC patients, ranging from simple benign cysts to more complex cystic disease resembling autosomal dominant polycystic kidney disease. Generally benign but contribute to renal functional decline in some patients.

• Pulmonary involvement (lymphangioleiomyomatosis): Occurs in 1-4% of TSC patients, predominantly in women of reproductive age, causing progressive lung disease. This manifestation involves proliferation of smooth muscle cells in the lungs leading to cyst formation and progressive airflow obstruction. Presents with dyspnea, reduced exercise tolerance, and recurrent pneumothorax. TSC-associated LAM is distinct from sporadic LAM but shares pathophysiology involving dysregulated mTOR signaling. Management may include mTOR inhibitors (sirolimus) which can slow disease progression.

• Retinal hamartomas and achromic patches: Present in 40-50% of patients, including retinal astrocytic hamartomas appearing as white lesions. Rarely cause vision loss but important for diagnosis.

• Hepatic angiomyolipomas and cysts: Develop in up to 20% of patients but are usually asymptomatic and do not require intervention.

• Revised diagnostic criteria (2012 International Tuberous Sclerosis Complex Consensus Conference): TSC is diagnosed when a patient meets two major criteria OR one major and two minor criteria. These criteria are based on clinical and imaging findings and facilitate diagnosis prior to genetic confirmation. Major criteria include: (1) Cortical tubers on MRI, (2) Cardiac rhabdomyoma, (3) Lymphangioleiomyomatosis (LAM), (4) Renal angiomyolipomas (≥2), (5) Retinal astrocytic hamartomas, (6) Recurrent seizures, (7) Facial angiofibromas (≥3), (8) Hypomelanotic macules (≥3), (9) Shagreen patch, (10) Ungual or periungual fibromas (≥2), (11) Confirmed TSC1 or TSC2 mutation. Minor criteria include: (1) Confetti skin lesions, (2) Dental enamel pits (>3), (3) Intraoral fibromas, (4) Retinal achromic patch, (5) "Cerebral white matter migration lines," (6) Gliomas, (7) Noncardiac rhabdomyoma, (8) Renal cysts (multiple or bilateral), (9) Nonrenal hamartomas. Meeting these criteria allows clinical diagnosis without requiring genetic testing, though genetic confirmation is desirable when possible. Family members of confirmed TSC cases should be screened clinically even if genetic testing is not performed.

• Neuroimaging (brain MRI): Essential for diagnosis and prognostication. Cortical tubers appear as areas of focal cortical thickening with abnormal T2/FLAIR signal, representing dysplasia of cortical architecture. Typically multiple and bilateral. Tuber number and location correlate with seizure severity and cognitive impairment. White matter abnormalities including migration lines (linear areas of abnormal signal extending from cortex to ventricles) are highly specific for TSC. Subependymal nodules are hamartomas arising from the subependymal germinal matrix, appearing as small nodules lining the lateral ventricles. The critical clinical entity is subependymal giant cell astrocytoma (SEGA), a larger nodule (>1 cm) that may grow and obstruct cerebr

Immediate stabilisation

• Acute hemorrhage from a renal angiomyolipoma: resuscitate and obtain urgent selective arterial embolization (with peri-procedural corticosteroids for post-embolization syndrome) rather than nephrectomy — the International TSC Consensus Group stresses nephron-sparing management because disease is bilateral and lifelong.
• SEGA with acute obstructive hydrocephalus: neurosurgical emergency — CSF diversion and/or resection, not medical therapy.

Seizures — first line

• Vigabatrin (irreversible GABA-transaminase inhibitor) is the drug of choice for infantile spasms in TSC, supported by the AAN/Child Neurology Society infantile spasms practice guideline and the International TSC Consensus recommendations. This is the key exception: ACTH/corticotropin is first line for infantile spasms not due to TSC.
• Focal seizures: standard antiseizure medications (sodium-channel blockers such as oxcarbazepine, or levetiracetam) per usual epilepsy practice.

Escalation / disease-modifying therapy

• mTOR inhibitors: everolimus is FDA-approved as adjunctive therapy for TSC-associated refractory focal seizures, for SEGA not amenable to safe resection, and for renal AML (typically an asymptomatic, growing lesion above roughly 3 cm). Sirolimus is used for TSC-associated lymphangioleiomyomatosis with declining lung function or chylous effusion, per the ATS/JRS LAM guideline.
• Cannabidiol (pharmaceutical-grade) is FDA-approved for TSC-associated seizures.
• Topical sirolimus for facial angiofibromas; pulsed-dye/CO₂ laser as an alternative.

Definitive/surgical

• Epilepsy surgery (resection of the epileptogenic tuber after video-EEG and MRI/PET concordance) for drug-resistant focal epilepsy; vagus nerve stimulation or ketogenic diet when resection is not feasible.
• Rhabdomyomas usually regress — resect only for obstruction or refractory arrhythmia.

Cautions/contraindications

• Vigabatrin causes irreversible peripheral visual field constriction and requires REMS enrollment with serial ophthalmologic testing.
• mTOR inhibitors are immunosuppressive: avoid live vaccines, hold before elective surgery for wound healing, and expect reduced levels with enzyme-inducing antiseizure drugs (CYP3A4).
• Estrogen-containing contraceptives are generally avoided in LAM.

Neurologic

• Subependymal giant cell astrocytoma (SEGA): a subependymal nodule near the foramen of Monro enlarges and blocks CSF egress → obstructive hydrocephalus. Signalled by new morning headache, vomiting, papilledema, declining school performance, or a change in seizure pattern. Neurosurgical emergency.
• Drug-resistant epilepsy and status epilepticus: hyperexcitable dysplastic cortex in tubers; roughly a third have medically refractory seizures. Convulsive status epilepticus is an emergency.
• TSC-associated neuropsychiatric disorders (TAND): intellectual disability, autism spectrum disorder, ADHD — driven by mTORC1-mediated dendritic/synaptic dysregulation and by early-onset seizures.

Renal

• Angiomyolipoma hemorrhage (Wunderlich syndrome): aneurysmal, elastin-poor vessels within the tumor rupture into the retroperitoneum. Flank pain, gross hematuria, hypotension, falling hematocrit — emergency; the leading cause of TSC mortality in adults.
• Chronic kidney disease/ESRD from cumulative AML burden, cyst disease, and repeated interventions; rarely renal cell carcinoma (unlike AML, it lacks macroscopic fat).

Pulmonary

• LAM with spontaneous pneumothorax: cystic destruction by proliferating smooth-muscle-like cells; sudden pleuritic pain and dyspnea in a young woman — tension pneumothorax is an emergency. Chylothorax and progressive obstructive physiology also occur.

Cardiac

• Rhabdomyoma: inflow/outflow obstruction, arrhythmia, and accessory-pathway tachyarrhythmias (WPW-type pre-excitation); in utero, large tumors can cause hydrops.

Treatment-related

• Vigabatrin: irreversible concentric peripheral visual field loss from retinal toxicity; also reversible intramyelinic edema on infant MRI. Detected only by scheduled ophthalmologic/ERG testing since young children do not report it.
• mTOR inhibitors (everolimus/sirolimus): aphthous stomatitis (most common, dose-limiting), hyperlipidemia, hyperglycemia, proteinuria, impaired wound healing, infection from immunosuppression, and non-infectious interstitial pneumonitis — new dry cough and hypoxemia on therapy demands imaging and drug interruption.
• Cannabidiol: transaminase elevation, especially with concomitant valproate; sedation with clobazam.
• Embolization: post-embolization syndrome (fever, pain, nausea) and nephron loss.

• **Hypomelanotic (ash-leaf) macules are the earliest sign: in an infant with seizures, the single best next step is a Wood's lamp examination** of the skin, followed by brain MRI and echocardiography.
• Infantile spasms + hypsarrhythmia + hypopigmented macules = TSC, and vigabatrin is first line here. The classic distractor is ACTH, which is first line for infantile spasms of other causes. Vigabatrin's toxicity is irreversible peripheral visual field loss, requiring serial ophthalmology under a REMS program.
• Cardiac rhabdomyoma is the most common cardiac tumor of infancy/childhood and is the manifestation most likely to be found prenatally; it usually regresses spontaneously, so asymptomatic lesions are observed, not resected. Its presence should trigger a TSC evaluation.
• SEGA sits at the foramen of Monro — the exam hinge is new headache/vomiting/papilledema signalling obstructive hydrocephalus. Options are surgical resection or everolimus; an mTOR inhibitor is the answer when the lesion is not safely resectable.
• Renal angiomyolipoma contains macroscopic fat on CT/MRI — that fat is what distinguishes it from renal cell carcinoma. For a bleeding AML the answer is selective arterial embolization, not nephrectomy; for an asymptomatic growing AML it is everolimus (International TSC Consensus Group).
• The one association examiners love: TSC1 encodes hamartin, TSC2 encodes tuberin; the complex is a GAP for Rheb, so loss of function → constitutive mTORC1 activation → rapalog therapy works. TSC2 disease is the more severe phenotype.
• LAM occurs almost exclusively in women of reproductive age: recurrent spontaneous pneumothorax plus diffuse thin-walled cysts on chest CT; treat with sirolimus (ATS/JRS guideline).
• Distractors to avoid: adenoma sebaceum is angiofibroma, not acne and not sebaceous; do not confuse TSC with Sturge–Weber (port-wine stain, leptomeningeal angioma, tram-track calcifications), NF1 (café-au-lait, Lisch nodules), or VHL (hemangioblastoma, clear cell RCC).